Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment

Nephrology Dialysis Transplantation

Volumn 21, Issue 1, 2006, Pages 101-106

  Vogt, Liffert ^a   Laverman, Gozewijn D ^a   van Tol, Arie ^a,b   Groen, Albert K ^c   Navis, Gerjan ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoproteins; Cellular cholesterol efflux; Dual RAAS blockade; PLTP; Pre HDL; Proteinuria

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LISINOPRIL; LOSARTAN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL TRANSPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FIBROBLAST CULTURE; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROBLAST; STATISTICAL ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEINS; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LISINOPRIL; LOSARTAN; MALE; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PROBABILITY; PROGNOSIS; PROTEINURIA; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 30344465325     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi068     Document Type: Article

References (20)

1. Joven J, Villabona C, Vilella E et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323: 579-584
2. Deighan CJ, Caslake MJ, McConnell M et al. The atherogenic lipoprotein phenotype: Small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis 2001; 157: 211-220
3. Vogt L, Laverman GD, Dullaart RPF, Navis GJ. Lipid management in the proteinuric patient: Do not overlook the importance of proteinuria reduction. Nephrol Dial Transplant 2004; 19: 5-8
4. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-228
5. Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithincholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 1051-1069
6. Rye KA, Jauhiainen M, Barter PJ, Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 1998; 39: 613-622
7. Muls E, Rosseneu M, Daneels R et al. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 1985; 54: 225-237
8. Dullaart RPF, Gansevoort RT, Dikkeschei LD et al. Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 1993; 44: 91-97
9. Ruggenenti P, Mise N, Pisoni R et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107: 586-592
10. Gansevoort RT, Heeg JE, Dikkeschei LD et al. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244-250
11. Speijer H, Groener JE, Van Ramshorst E, Van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991; 90: 159-168
12. De Vries R, Kerstens MN, Sluiter WJ, Groen AK, Van Tol A, Dullaart RPF. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005; 48: 1105-1113
13. Liang K, Vaziri ND. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 1999; 56: 621-626
14. Yancey PG, Bortnick AE, Kellner-Weibel G et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23: 712-719
15. Hovingh GK, Van Wijland MJ, Brownlie A et al. The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 2003; 44: 1251-1255
16. Favari E, Lee M, Calabresi L et al. Depletion of pre-β-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004; 279: 9930-9936
17. Oram JF, Wolfbauer G, Vaughan AM et al. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 2003; 278: 52379-52385
18. Van Haperen R, Van Tol A, Van Gent T et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277: 48938-48943
19. Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 1857-1862
20. Nofer JR, Kehrel B, Fobker M et al. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16